Founded in 1990, the IMF is the world's first and largest myeloma-specific foundation in the world. With more than 525,000 members in 140 countries, the IMF serves myeloma patients, family members, and the medical community.
For Newly Diagnosed Multiple Myeloma Patients
In this section, learn more about first steps you can take if you have a new multiple myeloma diagnosis. Multiple myeloma is a highly treatable disease. Many patients live long and productive lives after diagnosis. Both survival and quality of life for myeloma patients are improving steadily.
We encourage you to learn as much as possible about myeloma and to seek out the best care possible. Start by understanding the disease, then proceed to learn about tests, treatments, supportive care, and survivorship.
Knowledge is power. Developing a working knowledge of myeloma and how it is monitored and treated can help you reduce anxiety, gain a sense of control, and make communication with your healthcare team much more effective.
Your healthcare team will typically include most of these members:
- Your hematologist-oncologist, preferably a myeloma specialist, if possible.
- A primary care physician or family doctor.
- A nurse or nurse practitioner.
- An orthopedic surgeon (bone specialist).
- A pharmacist.
- A nephrologist (kidney specialist).
- A dentist or oral surgeon.
The best outcome for the patient results when the members of the healthcare team communicate with each other and with the patient or designated caregiver.
The IMF provides a wide range of programs in the areas of Research, Education, Support, and Advocacy. Learn more in the About Us section of this website.
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologist/oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape. Additionally, Dr. Brian G.M. Durie reviews and approves all medical content on this website.
Last Medical Review: March 1, 2019